Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.
Biogen
Posted inNeuroscience, New Drugs, Rare/Orphan Diseases, Regulatory
Zolgensma: Gene Therapy That Cure Spinal Muscular Atrophy. The Most Comprehensive Review
Novartis revealed the most expensive drug in the world. And it is amazing.